Utah Medical Products annual ebitda
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Utah Medical Products EBITDA Growth & History (UTMD)
Utah Medical Products's calculated EBITDA was $14.4M for fiscal 2025.
View full Utah Medical Products company overviewUtah Medical Products annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $14.4M | −$2.0M | −12.42% |
| 2024 | 2024-12-31 | $16.4M | −$6.7M | −29.03% |
| 2023 | 2023-12-31 | $23.1M | −$3.7M | −13.90% |
| 2022 | 2022-12-31 | $26.8M | $658,000 | +2.52% |
| 2021 | 2021-12-31 | $26.2M | $5.3M | +25.30% |
| 2020 | 2020-12-31 | $20.9M | −$3.6M | −14.70% |
| 2019 | 2019-12-31 | $24.5M | $5.0M | +25.76% |
| 2018 | 2018-12-31 | $19.5M | −$209,000 | −1.06% |
| 2017 | 2017-12-31 | $19.7M | $2.9M | +17.11% |
| 2016 | 2016-12-31 | $16.8M | $527,000 | +3.24% |
| 2015 | 2015-12-31 | $16.3M | −$569,000 | −3.38% |
| 2014 | 2014-12-31 | $16.8M | $1.4M | +9.07% |
| 2013 | 2013-12-31 | $15.4M | −$410,000 | −2.59% |
| 2012 | 2012-12-31 | $15.8M | $3.3M | +26.30% |
| 2011 | 2011-12-31 | $12.5M | $3.1M | +32.30% |
| 2010 | 2010-12-31 | $9.5M | −$502,000 | −5.03% |
| 2009 | 2009-12-31 | $10.0M | — | — |
Utah Medical Products quarterly ebitda
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.9M | −$1.1M | −27.03% |
| Q1 2026 | 2026-03-31 | $3.2M | −$624,000 | −16.16% |
| Q4 2025 | 2025-12-31 | $3.2M | −$460,000 | −12.61% |
| Q3 2025 | 2025-09-30 | $3.4M | −$706,000 | −17.34% |
| Q2 2025 | 2025-06-30 | $3.9M | −$179,000 | −4.35% |
| Q1 2025 | 2025-03-31 | $3.9M | −$690,000 | −15.16% |
| Q4 2024 | 2024-12-31 | $3.6M | −$1.3M | −26.62% |
| Q3 2024 | 2024-09-30 | $4.1M | −$1.7M | −29.09% |
| Q2 2024 | 2024-06-30 | $4.1M | −$2.1M | −33.47% |
| Q1 2024 | 2024-03-31 | $4.6M | −$1.6M | −26.46% |
| Q4 2023 | 2023-12-31 | $5.0M | −$1.8M | −27.00% |
| Q3 2023 | 2023-09-30 | $5.7M | −$1.1M | −16.47% |
| Q2 2023 | 2023-06-30 | $6.2M | −$630,000 | −9.24% |
| Q1 2023 | 2023-03-31 | $6.2M | −$127,000 | −2.01% |
| Q4 2022 | 2022-12-31 | $6.8M | −$123,000 | −1.77% |
| Q3 2022 | 2022-09-30 | $6.9M | −$44,000 | −0.64% |
| Q2 2022 | 2022-06-30 | $6.8M | $223,000 | +3.38% |
| Q1 2022 | 2022-03-31 | $6.3M | $602,000 | +10.53% |
| Q4 2021 | 2021-12-31 | $6.9M | −$4.0M | −36.74% |
| Q3 2021 | 2021-09-30 | $6.9M | $3.2M | +84.60% |
| Q2 2021 | 2021-06-30 | $6.6M | $4.5M | +208.75% |
| Q1 2021 | 2021-03-31 | $5.7M | $1.7M | +41.53% |
| Q4 2020 | 2020-12-31 | $11.0M | −$41,000 | −0.37% |
| Q3 2020 | 2020-09-30 | $3.7M | −$795,000 | −17.50% |
| Q2 2020 | 2020-06-30 | $2.1M | −$2.5M | −54.11% |
| Q1 2020 | 2020-03-31 | $4.0M | −$242,000 | −5.65% |
| Q4 2019 | 2019-12-31 | $11.0M | $6.5M | +146.79% |
| Q3 2019 | 2019-09-30 | $4.5M | −$42,000 | −0.92% |
| Q2 2019 | 2019-06-30 | $4.7M | −$594,000 | −11.31% |
| Q1 2019 | 2019-03-31 | $4.3M | −$891,000 | −17.23% |
| Q4 2018 | 2018-12-31 | $4.5M | −$288,000 | −6.07% |
| Q3 2018 | 2018-09-30 | $4.6M | −$254,000 | −5.25% |
| Q2 2018 | 2018-06-30 | $5.3M | $53,000 | +1.02% |
| Q1 2018 | 2018-03-31 | $5.2M | $280,000 | +5.72% |
| Q4 2017 | 2017-12-31 | $4.7M | $965,000 | +25.54% |
| Q3 2017 | 2017-09-30 | $4.8M | $745,000 | +18.20% |
| Q2 2017 | 2017-06-30 | $5.2M | $734,000 | +16.44% |
| Q1 2017 | 2017-03-31 | $4.9M | $430,000 | +9.64% |
| Q4 2016 | 2016-12-31 | $3.8M | −$186,000 | −4.69% |
| Q3 2016 | 2016-09-30 | $4.1M | −$67,000 | −1.61% |
| Q2 2016 | 2016-06-30 | $4.5M | $345,000 | +8.38% |
| Q1 2016 | 2016-03-31 | $4.5M | $435,000 | +10.80% |
| Q4 2015 | 2015-12-31 | $4.0M | −$493,000 | −11.06% |
| Q3 2015 | 2015-09-30 | $4.2M | −$5,000 | −0.12% |
| Q2 2015 | 2015-06-30 | $4.1M | −$98,000 | −2.32% |
| Q1 2015 | 2015-03-31 | $4.0M | $27,000 | +0.68% |
| Q4 2014 | 2014-12-31 | $4.5M | $747,000 | +20.13% |
| Q3 2014 | 2014-09-30 | $4.2M | $349,000 | +9.15% |
| Q2 2014 | 2014-06-30 | $4.2M | $349,000 | +9.02% |
| Q1 2014 | 2014-03-31 | $4.0M | −$45,000 | −1.11% |
| Q4 2013 | 2013-12-31 | $3.7M | $634,000 | +20.60% |
| Q3 2013 | 2013-09-30 | $3.8M | −$304,000 | −7.38% |
| Q2 2013 | 2013-06-30 | $3.9M | $151,000 | +4.06% |
| Q1 2013 | 2013-03-31 | $4.0M | −$891,000 | −18.05% |
| Q4 2012 | 2012-12-31 | $3.1M | $761,000 | +32.86% |
| Q3 2012 | 2012-09-30 | $4.1M | $399,000 | +10.72% |
| Q2 2012 | 2012-06-30 | $3.7M | −$372,000 | −9.10% |
| Q1 2012 | 2012-03-31 | $4.9M | $2.5M | +103.67% |
| Q4 2011 | 2011-12-31 | $2.3M | — | — |
| Q3 2011 | 2011-09-30 | $3.7M | — | — |
| Q2 2011 | 2011-06-30 | $4.1M | — | — |
| Q1 2011 | 2011-03-31 | $2.4M | — | — |
Utah Medical Products ebitda trends
Over the last five fiscal years, Utah Medical Products's ebitda decreased from $20.9M to $14.4M, a change of −$6.5M. The latest reported quarter, Q2 2026, shows $2.9M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Utah Medical Products source filings ↗Community posts
Utah Medical launches $75-per-share self-tender offer
Utah Medical Products ($UTMD) commenced a tender offer to repurchase up to 650,000 common shares at $75 each. At full acceptance, the share purchase would total $48.75 million before related costs. The offer follows previously announced ter ...
